利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.023 秒)

    Substituted alkylene diamine compounds
    1.
    发明授权
    Substituted alkylene diamine compounds 失效
    取代的亚烷基二胺化合物

    公开(公告)号：US06638970B2

    公开(公告)日：2003-10-28

    申请号：US09790932

    申请日：2001-02-22

    申请人： Elfaith Elzein ,  Jeff Zablocki ,  Tim Marquart

    发明人： Elfaith Elzein ,  Jeff Zablocki ,  Tim Marquart

    IPC分类号： A01N3718

    CPC分类号： C07C237/20 ,  C07D317/58 ,  C07D317/64

    摘要： Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

    摘要翻译： 新的通式化合物及其药学上可接受的酸加成盐，其中所述化合物可用于治疗以保护骨骼肌免受创伤损伤或保护肌肉或全身性疾病如间歇性跛行后的骨骼肌，以治疗休克 条件，以维持移植物中使用的供体组织和器官，治疗包括心房和室性心律失常的心血管疾病，Prinzmetal（变体）心绞痛，稳定性心绞痛和运动诱发的心绞痛，充血性心脏病和心肌梗塞。

    A2B adenosine receptor antagonists
    2.
    发明申请
    A2B adenosine receptor antagonists 有权
    A2B腺苷受体拮抗剂

    公开(公告)号：US20050119287A1

    公开(公告)日：2005-06-02

    申请号：US10973167

    申请日：2004-10-26

    申请人： Rao Kalla ,  Elfatih Elzein ,  Tim Marquart ,  Thao Perry ,  Xiaofen Li ,  Jeff Zablocki

    发明人： Rao Kalla ,  Elfatih Elzein ,  Tim Marquart ,  Thao Perry ,  Xiaofen Li ,  Jeff Zablocki

    IPC分类号： A61K31/519 ,  C07D487/02 ,  C07D487/04

    CPC分类号： C07D487/04

    摘要： Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

    摘要翻译： 公开了作为具有以下结构的A 2 B 2腺苷受体拮抗剂的新化合物：其中R 1和R 2独立地选自氢，任选地 取代的烷基，任选取代的环烷基，任选取代的芳基和任选取代的杂芳基，R 4是任选取代的杂芳基部分。 本发明的化合物可用于治疗各种疾病状态，包括哮喘，慢性阻塞性肺病，肺部炎症，肺气肿，糖尿病，炎症性胃肠道疾病，免疫/炎性疾病，心血管疾病，神经系统疾病以及与血管发生有关的疾病 。

    Substituted piperazine compounds
    5.
    发明授权
    Substituted piperazine compounds 失效
    取代的哌嗪化合物

    公开(公告)号：US06677336B2

    公开(公告)日：2004-01-13

    申请号：US09791134

    申请日：2001-02-22

    申请人： Jeff Zablocki ,  Elfatih Elzein ,  Grigory Nudelman ,  Tim Marquart ,  Brent K. Blackburn ,  Venkata P. Palle

    发明人： Jeff Zablocki ,  Elfatih Elzein ,  Grigory Nudelman ,  Tim Marquart ,  Brent K. Blackburn ,  Venkata P. Palle

    IPC分类号： A61K31495

    CPC分类号： C07D241/04 ,  C07D241/08 ,  C07D241/42 ,  C07D295/15 ,  C07D317/54 ,  C07D317/58

    摘要： Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

    摘要翻译： 新的通式化合物及其药学上可接受的酸加成盐，其中所述化合物可用于治疗以保护骨骼肌免受创伤损伤或保护肌肉或全身性疾病如间歇性跛行后的骨骼肌，以治疗休克 条件，以维持移植物中使用的供体组织和器官，治疗包括心房和室性心律失常的心血管疾病，Prinzmetal（变体）心绞痛，稳定性心绞痛和运动诱发的心绞痛，充血性心脏病和心肌梗塞。

    Aralkyl substituted piperazine compounds
    6.
    发明授权
    Aralkyl substituted piperazine compounds 失效
    芳烷基取代的哌嗪化合物

    公开(公告)号：US06552023B2

    公开(公告)日：2003-04-22

    申请号：US09791133

    申请日：2001-02-22

    申请人： Jeff Zablocki ,  Elfatih Elzein ,  Brent K. Blackburn ,  Tim Marquart ,  Prabha N. Ibrahim ,  Venkata P. Palle

    发明人： Jeff Zablocki ,  Elfatih Elzein ,  Brent K. Blackburn ,  Tim Marquart ,  Prabha N. Ibrahim ,  Venkata P. Palle

    IPC分类号： A61K31495

    CPC分类号： C07D295/15 ,  C07D241/04 ,  C07D241/08 ,  C07D241/42 ,  C07D317/54 ,  C07D317/58

    摘要： Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

    摘要翻译： 新的通式化合物及其药学上可接受的酸加成盐，其中所述化合物可用于治疗以保护骨骼肌免受创伤损伤或保护肌肉或全身性疾病如间歇性跛行后的骨骼肌，以治疗休克 条件，以维持移植中使用的供体组织和器官，治疗包括心房和室性心律失常的心血管疾病，Prinzmetal（变体）心绞痛，稳定性心绞痛和运动诱发的心绞痛，充血性心脏病和心肌梗死。